Replies to post #125332 on Biotech Values

[mcbio]

why are you attacking me.

I'm not attacking you at all. I just strongly disagree with what you're saying.

What do you think are the odds of that deal being done in less than two months?...It was a pretty complex transaction

ARRY was already partnered with Genentech on another program so it could have been done in relatively short order. And I'll stick with the other points I made in #msg-66329214 about Conway's prior buying history or lack thereof of not buying ahead of much bigger deals and the fact there was no reason to think this deal was going to move the stock that much anyways (and it didn't). It just doesn't add up IMHO. Anyways, we've debated this enough so let's move on.

Any comments on the OS numbers from the DTIC arm in the Zelboraf trial and what that may mean for the ongoing Phase 2 selumetinib trial in a similar patient population (#msg-66288817 )?